bepafant

08/01/1995 - "The present study uses a perfused porcine pancreas model to investigate the role of PAF in pancreatic ischemia and the effect of the PAF antagonist bepafant on pancreas preservation. "
11/01/2003 - "The platelet-activating factor (PAF) antagonist WEB 2170 BS, however, significantly improved recovery of external heart work during ischemia and in reperfusion. "
01/01/2007 - "Combined use of WEB2170 and HBO therapy can reduce ischemia and reperfusion injury to the skeletal muscle in a rabbit model."

01/01/2007 - "The PAF antagonist WEB2170 (10 mg/kg i.v.) was administered 30 min before induction of pancreatitis. "
05/01/1999 - "Six hours after acute pancreatitis induction, rats were randomized to therapy with ET-RA (50 mg/kg LU-135252), PAF-RA (82 microg/kg WEB-2170), or NaCl 0.9% (volume equivalent). "
01/01/2007 - "We found that liver cells produce nitric oxide (NO) only under lipopolysaccharide stimulation and that WEB-2170 treatment reduces the NO production by liver cells in the pancreatitis group only. "
01/01/1995 - "Although the inhibition induced by BN-52021 suggests the involvement of PAF in cerulein-pancreatitis, the lack of effect of WEB-2170 reported here does not allow a definite conclusion. "
01/01/1995 - "At these concentrations, BN-52021 was effective at inhibiting cerulein-induced pancreatitis (60-70% of inhibition) whereas WEB-2170 had no significant effect. "

01/01/2012 - "Animals received the PAFR antagonists, WEB2170 or PCA4248 (5 mg/kg body weight) or vehicle, by peritumoral daily injection for 5 days. "
01/01/1996 - "In another 5 rabbits, the same amount of labelled CS was instilled by tracheal infusion within 5 min. A third group of 5 animals received 3 mg/kg body weight of the PAF antagonist WEB 2170 before CS bolus instillation. "
12/01/1994 - "WEB 2170 significantly improved inulin and PAH clearances at 36 weeks (inulin clearance: Nx, 182 +/- 28 microliters/min/100 gm body weight; Nx plus WEB, 284 +/- 19 microliters/min/100 gm body weight; p < 0.05; PAH clearance: Nx, 718 +/- 85 microliters/min/100 gm body weight; Nx plus WEB, 1215 +/- 103 microliters/min/100 gm body weight; p < 0.05). "
02/01/1993 - "The administration of two structurally unrelated platelet-activating factor-receptor antagonists (SDZ 63-675, 5 mg/kg body weight, and WEB 2170, 5 mg/kg body weight) before reperfusion significantly reduced the accumulation of PMN, as well as the hemodynamic alterations and the size of necrotic area. "
07/01/1993 - "On the basis of the fact that oxygen radical-catalyzed peroxidation of phospholipids results in the generation of fragments with short sn2 residues, which besides authentic platelet-activating factor (PAF), activate the receptor for PAF on leukocytes and thereby induce leukocyte adhesion, we asked whether pretreatment of hamsters with a specific PAF receptor antagonist (WEB2170; 1 mg/kg of body weight IV, 10 minutes before oxLDL) attenuates leukocyte adhesion after injection of oxLDL (4 mg/kg of body weight IV, oxidized by 7.5 mumol/L Cu2+ for 18 hours at 37 degrees C). "

01/28/1992 - "Intraperitoneal treatment with WEB 2170 1 h before challenge reduced dose dependently the edema in boosted mice but did not modify the reaction in unboosted mice. "
01/28/1992 - "It is noteworthy that WEB 2170 was more effective against PAF-induced paw edema in unboosted than in boosted mice, the maximum inhibition of 84% being reached at 16 mg/kg. In addition, topical and selective desensitization to PAF inhibited the edema caused by antigen only in boosted animals. "
01/28/1992 - "Interference of the PAF antagonist, WEB 2170, with the paw edema induced by antigen in boosted or unboosted sensitized mice was investigated. "
01/01/1991 - "Mice were treated before induction of edema with the PAF antagonists BN52021 (10 mg/kg, ip), PCA4248 (10 mg/kg, po) or WEB2170 (10 mg/kg, ip), the lipoxygenase inhibitor EP10161 (10 mg/kg, ip), the cyclo-oxygenase inhibitor aspirin (250 mg/kg, po), or with the mixed cyclo-lipoxygenase inhibitor BW755C (50 mg/kg, ip). "
01/01/1991 - "In different disease related animal models of asthma selective and potent hetrazepine paf-antagonists (like the hetrazepines WEB 2086 and WEB 2170) inhibit (i) allergen-induced bronchoconstriction, (ii) antigen-induced infiltrations of eosinophils, (iii) lung-edema formation by antigen, (iv) late phase response and (v) bronchial hyperreactivity to antigen. "

06/01/1994 - "All PAF antagonists showed a concentration-dependent inhibition of the exocytosis of activated neutrophils, the PAF-inhibitor WEB 2170 being the most potent, with an IC(50) = 0.2 μg/ml while MtL showed an IC(50) = 160 μg/ml. It is concluded that the higher GFR seen after acute renal failure and treatment with MtL, could, in part, be due to a PAF-antagonistic effect."